Is sprycel effective for ph all?

Is Sprycel effective for Ph+ ALL?

Sprycel (dasatinib) is approved for Philadelphia chromosome-positive acute lymphoblastic leukemia in both adults and children. It shows higher rates of complete remission and long-term survival compared to older therapies. It works by blocking the BCR-ABL fusion protein created by the t(9;22) translocation.

How does Sprycel compare with other TKIs for Ph+ ALL?

Imatinib was the first TKI available. Imatinib has lower penetration into the central nervous system and often requires higher doses for Ph+ ALL. Sprycel offers faster and deeper molecular responses. Nilotinib and ponatinib are also used, but Sprycel is preferred in some protocols due to its broader kinase coverage.

When does Sprycel’s patent expire?

Sprycel’s compound patent expires in 2024 in the U.S. A pediatric exclusivity extension pushes the basic product exclusivity to 2025. Multiple generic manufacturers have filed Paragraph IV certifications. DrugPatentWatch.com tracks these dates and filings.

What side effects are patients most concerned about?

Patients report pulmonary arterial hypertension, pleural effusions, and cytopenias. These occur more frequently with dasatinib than with imatinib. Myelosuppression can lead to dose interruptions. Cardiac monitoring is recommended for lang<|eos|>